Cancer immunology, immunotherapy : CII最新文献

{"title":"Intracranially injected chimeric antigen receptor T cells eradicate glioblastoma cells but have limited potential to persist in the brain in a syngeneic mouse model.","authors":"Koki Murakami, Noriyuki Kijima, Hideki Kuroda, Tetsuro Tachi, Shunya Ikeda, Kanji Nakagawa, Yuki Wada, Tatsuya Hagioka, Naoko Hatanaka, Ryuichi Hirayama, Haruhiko Kishima, Naoki Hosen","doi":"10.1007/s00262-026-04475-z","DOIUrl":"10.1007/s00262-026-04475-z","url":null,"abstract":"<p><p>Glioblastoma multiforme (GBM) is among the most malignant primary brain tumors, necessitating the development of novel therapies. Intracranial injection of chimeric antigen receptor (CAR)-T cell therapy is effective against GBM. However, whether intracranially injected CAR-T cells persist in the brain for long periods is unclear. In this study, we established a syngeneic murine model of GBM by injecting GL261 murine GBM cells expressing human B7-H3. After confirming tumor engraftment, murine T cells transduced with CAR-targeting human B7-H3 were injected intratumorally. Reduced tumor burden and enhanced survival were observed in mice injected with B7-H3 CAR-T cells compared with those injected with control T cells. CAR-T cells were distinctly detected in the brain 1 week after CAR-T cell injection, but disappeared 2 weeks after injection. In the syngeneic mouse model, intracranially injected CAR-T cells have the potential to eradicate GBM but do not persist in the brain for long, suggesting that intracranial injections of CAR-T cells need to be repeatedly administered, as has been done in several clinical trials. It will be important to develop strategies to enhance persistence of CAR-T cells in the brain.</p>","PeriodicalId":520581,"journal":{"name":"Cancer immunology, immunotherapy : CII","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13638904/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148407682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world treatment patterns and early outcomes in advanced intrahepatic cholangiocarcinoma: a descriptive case series.","authors":"Runze Yu, Hong Zhao, Dong Yan","doi":"10.1007/s00262-026-04385-0","DOIUrl":"10.1007/s00262-026-04385-0","url":null,"abstract":"<p><p>Intrahepatic cholangiocarcinoma (ICC) has a poor prognosis, with 70-80% of patients presenting advanced/metastatic disease. Conventional first-line chemotherapies have limitations, and targeted-immunotherapy combinations need real-world validation. This retrospective, single-center case series enrolled 12 advanced ICC patients to describe the real-world clinical characteristics, treatment patterns which including lenvatinib-based targeted-immunotherapy with or without Transarterial Interventional Therapies (TAIT) and conventional chemotherapy, as well as early efficacy and safety outcomes; and to generate preliminary hypotheses for subsequent prospective studies, without any intention to compare the efficacy of different regimens. Among the 12 patients, objective response rate was 33.3%, and disease control rate 83.33%. Nine received lenvatinib + PD-1/PD-L1 inhibitors (targeted-immunotherapy group), and 3 received systemic chemotherapy. Among patients receiving lenvatinib + PD-1/PD-L1 inhibitors, 22.22% experienced grade ≥ 3 treatment-related adverse events (TRAEs) with a median treatment duration of 9.0 months; among patients receiving conventional chemotherapy, 66.7% experienced grade ≥ 3 TRAEs with a median treatment duration of 19.0 months. Early TAIT (≤ 2 weeks) was associated with higher tumor reduction (mean 30.52 vs. 7.69% for non-early), which may help alleviate tumor-related symptoms in patients with high initial tumor burden. Baseline CA19-9 and albumin/globulin ratio showed exploratory potential associations with treatment efficacy without formal statistical analysis; larger initial diameter correlated with better response. This study describes that lenvatinib + Immune Checkpoint Inhibitors (ICIs) combined with early TAIT may be a feasible multimodal strategy used in real-world practice for advanced ICC, with preliminary observations of feasibility. Limitations include small single-center sample and short follow-up. The high heterogeneity of treatment regimens may also limit the comparability of efficacy and safety. Larger prospective studies are needed.</p>","PeriodicalId":520581,"journal":{"name":"Cancer immunology, immunotherapy : CII","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13631205/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148407766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CXCL13-CXCR5 signaling in CD8⁺ T cell recruitment and lymphoid immune organization in clear cell renal cell carcinoma.","authors":"Daniel D Shapiro, Kye D Nichols, Moon Hee Lee, Pavlos Msaouel, Yuanshan Li, Yang Zong, Rong Hu, Wei Huang, Karla Esbona, Toshi Kinoshita, Paz Lotan, Daniel F Roadman, Everlyne Nkadori, Stephanie M McGregor, David J Beebe, Sheena C Kerr, Christian M Capitini, Edwin Jason Abel","doi":"10.1007/s00262-026-04489-7","DOIUrl":"10.1007/s00262-026-04489-7","url":null,"abstract":"<p><p>Clear cell renal cell carcinoma (ccRCC) exhibits heterogeneity in immune infiltration and clinical outcomes, but the mechanisms governing recruitment and organization of tumor-reactive CD8⁺ T cells remain incompletely defined. We investigated the role of the CXCL13-CXCR5 axis in shaping CD8⁺ T cell recruitment, differentiation, and immune organization in high-risk, non-metastatic ccRCC. Human tumor, plasma, and matched adjacent kidney specimens were analyzed using ELISA, quantitative PCR, migration assays, multiplex immunofluorescence, single-cell RNA sequencing, spatial transcriptomics, and a syngeneic mouse model. CXCL13 was among the most upregulated chemokines in ccRCC relative to matched normal kidney and was embedded within a CD8⁺ T cell-associated inflammatory transcriptional program. In transwell and microphysiological system (MPS) assays, CXCL13 promoted CD8⁺ T cell migration, enriched CXCR5⁺ cells among migrating CD8⁺ T cells and showed reduced migration after CXCL13 or CXCR5 blockade. Single-cell analyses identified CXCR5 expression within stem-like CD8⁺ T cell states associated with TCF7 and IL7R, whereas CXCL13 associated with later cytotoxic/exhausted states along a continuous differentiation landscape. Spatial transcriptomics demonstrated that stem-like CD8⁺ T cells localized within structured lymphoid aggregates enriched for B cells, coordinated CXCL13/CXCR5 expression, and signaling programs. In vivo, tumor-derived CXCL13 suppressed tumor growth, increased intratumoral CD8⁺ T cell infiltration, and enriched CXCR5⁺TCF1⁺CD8⁺ stem-like T cells. In human tumors, higher CXCL13 expression correlated with increased CXCR5⁺CD8⁺ T cell infiltration and improved recurrence-free survival. These findings identify CXCL13 as a regulator of immune recruitment and niche organization and support the CXCL13-CXCR5 axis as a biomarker and possible therapeutic target in ccRCC.</p>","PeriodicalId":520581,"journal":{"name":"Cancer immunology, immunotherapy : CII","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13631209/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148400389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and feasibility of 5T4 antibody-coupled allogeneic NK cell therapy for solid tumors: a first-in-human phase 1 trial.","authors":"Liangjie Sun, Peiwen Ma, Zhenwei Miao, Na Su, Jinduo Bian, Shuhang Wang, Ning Li","doi":"10.1007/s00262-026-04481-1","DOIUrl":"10.1007/s00262-026-04481-1","url":null,"abstract":"<p><strong>Background: </strong>Patients with unresectable locally advanced or metastatic solid tumors have limited therapeutic options. Antibody-guided allogeneic natural killer (NK) cell therapy represents a novel immunotherapeutic strategy to enhance tumor targeting and cytotoxicity by coupling NK cells with tumor-specific antibodies targeting antigens such as 5T4.</p><p><strong>Objective: </strong>To evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of IBR854, a non-viral, non-genetically modified, 5T4 antibody-coupled allogeneic NK cell therapy, in patients with advanced solid tumors.</p><p><strong>Patients and methods: </strong>This open-label, first-in-human phase 1 dose-escalation study enrolled 19 patients with unresectable locally advanced or metastatic solid tumors across five dose cohorts (3.0 × 10⁹-12.0 × 10⁹ cells per dose). Patients received intravenous IBR854 in a 3 + 3 escalation design. Safety, dose-limiting toxicities, adverse events, pharmacokinetics, anti-drug antibodies, and antitumor activity (RECIST v1.1) were assessed.</p><p><strong>Results: </strong>No dose-limiting toxicities were observed. The most common treatment-emergent adverse events were elevated interleukin levels (42.1%), infusion-related reactions (31.6%), and fever (21.1%). No anti-drug antibodies were detected. The disease control rate was 43.8%. Median progression-free survival was 43 days. Pharmacokinetic analysis based on transgene copy number showed a dose-dependent prolongation of T_max (0.867-3.433 h), with a relatively consistent half-life (1.390-2.648 h).</p><p><strong>Conclusions: </strong>IBR854 demonstrated an acceptable safety and tolerability profile and achieved disease stabilization in a subset of heavily pretreated patients with advanced solid tumors. These findings support further clinical development of 5T4-targeted antibody-coupled allogeneic NK cell therapy. Trial registration This study was registered at ClinicalTrials.gov (registration number: NCT06001684).</p>","PeriodicalId":520581,"journal":{"name":"Cancer immunology, immunotherapy : CII","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13619991/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148393182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Conserved minimal CD8 cytotoxic immune-state unit in an IL18R1-associated immune program in hepatocellular carcinoma.","authors":"Masamichi Kimura, Koji Nishikawa, Jun Imamura, Kiminori Kimura","doi":"10.1007/s00262-026-04487-9","DOIUrl":"10.1007/s00262-026-04487-9","url":null,"abstract":"<p><strong>Background and aims: </strong>The conserved human correlate of interleukin-18 receptor 1 (IL-18R1)-associated immune states in hepatocellular carcinoma (HCC) remains undefined. We aimed to identify a minimal, reproducible, immune-state component associated with IL18R1 across independent human HCC cohorts and evaluate its clinical relevance.</p><p><strong>Methods: </strong>Publicly available single-cell RNA sequencing datasets from five independent HCC cohorts were analyzed using a unified framework. Paired tumor-adjacent cohorts were prioritized for primary analyses, whereas tumor-only cohorts served as supportive datasets. CD8 T cells were stratified by IL18R1 expression, and tumor-specific enrichment was quantified using difference-in-differences. We validated the spatial transcriptomics using a murine liver tumor Xenium dataset. Clinical relevance was evaluated using The Cancer Genome Atlas Liver Hepatocellular Carcinoma (TCGA-LIHC) bulk RNA-seq data.</p><p><strong>Results: </strong>IL18R1-positive CD8 T cells exhibited a tumor-specific, C-C motif chemokine ligand 5 (CCL5)-centered cytotoxic transcriptional program, consistently enriched across datasets. Alternative IL18R1 stratification confirmed the identified immune program's robustness. Spatial transcriptomics localized this cytotoxic state in tumor-associated CD8 T cells and highlighted increased expression of Ccl5 and Cxcr3. Tumor-only cohorts demonstrated substantial heterogeneity, highlighting the importance of paired cohort design. In TCGA-LIHC, a composite CCL5-centered cytotoxic core score, not CCL5 alone, was associated with improved overall survival, although this attenuated after adjusting for clinical covariates.</p><p><strong>Conclusions: </strong>The dominant human correlate of an IL18R1-associated immune state in HCC is a compact, CCL5-centered CD8 cytotoxic module, not a broad inflammatory response. This spatially validated unit provides a reproducible framework for HCC immune-state characterization and stratification.</p>","PeriodicalId":520581,"journal":{"name":"Cancer immunology, immunotherapy : CII","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13620086/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148393110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time-dependent cytokine landscapes in an ex vivo microfluidic glioblastoma platform.","authors":"Amr Moursi, Antonia Barry, Lauric Feugere, Alex Iles, Ian Scott, Shailendra Achawal, Chittoor Rajaraman, Pedro Beltran-Alvarez, John Greenman","doi":"10.1007/s00262-026-04486-w","DOIUrl":"10.1007/s00262-026-04486-w","url":null,"abstract":"<p><p>Glioblastoma (GBM) is the most common and aggressive astrocytic glioma of the central nervous system with a median survival of 15 months from diagnosis. Patient outcomes have improved only marginally over the past 20 years, and GBM research is limited by models that fail to preserve the native architecture and function of tumours over time. The aim of our study was to provide a physiologically and clinically relevant microfluidic environment for the study of GBM. We designed and validated a custom-built polymethyl methacrylate (PMMA) microfluidic perfusion platform, and successfully maintained ex vivo culture of intact, fresh, patient-derived GBM biopsies for up to 12 days. Cellular viability and tissue integrity were assessed by histology, apoptosis markers, and cytokine profiling, whilst cellular stress was quantified by lactate dehydrogenase (LDH) release. LDH levels initially decreased and then remained low and stable up to 12 days. Haematoxylin and eosin staining showed that tissue architecture was preserved, with mitotic figures post-perfusion. Cleaved PARP and Annexin V immunohistochemistry revealed no significant increase in apoptosis between pre- and post-perfused tissues at 8 or 12 days. Effluent cytokine analyses demonstrated sustained secretory activity with a time-dependent modulation (across 105 analytes: p = 0.0288). Quantitative ELISAs for seven cytokines (VEGF, MMP9, CHI3L1, IL-6, IL-8, Serpin-E1, Angiopoietin-2) corroborated cytokine analysis trends and correlated strongly with array data (p < 0.001), validating assay fidelity and biological signal. Collectively, biochemical, histological and secretome readouts show that intact GBM tissues remain viable, metabolically active and analysable on this platform for up to 12 days. The system provides a practical, physiologically relevant, model for longitudinal GBM studies and lays the groundwork for scalable translational testing of patient tissue.</p>","PeriodicalId":520581,"journal":{"name":"Cancer immunology, immunotherapy : CII","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13620026/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148393131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Macrophage heterogeneity in breast cancer microenvironment and development of a prognostic model: exploring TFF1 as a novel therapeutic target.","authors":"Lin Chen, Zhiqiang Chen, Bailu Shi, Lingli Chen, Guoren Zhou","doi":"10.1007/s00262-026-04354-7","DOIUrl":"https://doi.org/10.1007/s00262-026-04354-7","url":null,"abstract":"<p><strong>Backgrounds: </strong>Breast cancer (BRCA) represents the most prevalent malignancy globally, with projections indicating 3.2 million new cases anticipated by 2050. Current treatment modalities, encompassing surgical intervention, chemotherapy, and immunotherapy, are markedly hindered by treatment resistance and the inherent complexity of BRCA, thereby impeding effective disease management. Consequently, this study is designed to elucidate cellular heterogeneity within the tumor microenvironment (TME) and to identify prospective therapeutic targets, thus enabling individualized treatment approaches for individuals with BRCA, which remains crucial.</p><p><strong>Methods: </strong>GEO and TCGA databases were the sources of all analytical data employed in this investigation. Single-cell RNA sequencing data were employed to identify macrophage-associated genes in BRCA, followed by the development of a machine-learning-based prognostic model (PM) integrating data from TCGA and GEO databases. This model stratifies individuals into cohorts of either low or high risk, enabling a disparity evaluation in survival outcomes and tumor immune microenvironment characteristics. Gene co-expression patterns were examined through an analysis of gene co-expression network weighted by high dimension for screening pivotal central genes implicated in tumor immunity. Clinical PMs were subsequently constructed utilizing machine learning algorithms, with validation performed on training and test sets. Furthermore, XGBoost and LightGBM machine learning algorithms were implemented to pinpoint potential biomarkers. Ultimately, validation of these biomarkers was conducted through ELISA, CCK-8 assay, flow cytometry, Western blotting, and immunoprecipitation assays.</p><p><strong>Results: </strong>Findings indicated a pronounced elevation of TAMs in BRCA patients, with their phenotypic attributes exhibiting a strong correlation with prognosis. The developed clinical PM demonstrated high accuracy and robust predictive capability concerning survival rates of 1, 3, or 5 years. The comprehensive evaluation determined that high-risk cohort's immune microenvironment exhibited a greater inclination toward immune suppression, whereas the low-risk cohort was markedly predisposed to anti-tumor immune responses. Notably, the trifolium factor 1 (TFF1) gene was identified as a key determinant, with its overexpression being markedly associated with tumor invasiveness and immune evasion.</p><p><strong>Conclusions: </strong>The study underscores cellular heterogeneity inherent in BRCA TME, while PM, predicated on macrophage subpopulation-related genes, offers a novel approach for risk stratification and personalized therapeutic interventions for BRCA patients. Moreover, TFF1 has been established as a prospective therapeutic target, yielding important directions for developing specific treatment interventions.</p>","PeriodicalId":520581,"journal":{"name":"Cancer immunology, immunotherapy : CII","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148388517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A low-dose self-amplifying mRNA vaccine encoding HPV16 E6/E7 induces potent T-cell immunity and antitumor protection in mice.","authors":"Rui Xing, Shanshan Wang, Yixin Wang, Geng Chen, Rui Zhou, Xuelian Wang, Li Ma, Yongjun Yang, Sheng Li, Ming Zhao, Yinwei Zhang, Yuanyuan Fu, Fujie Cui, Gao Meng, Bin Zheng, Changyun Xiong, Youru Wang","doi":"10.1007/s00262-026-04411-1","DOIUrl":"10.1007/s00262-026-04411-1","url":null,"abstract":"<p><strong>Background: </strong>Human papillomavirus (HPV), particularly high-risk types such as HPV16, is associated with several malignancies, including cervical cancer. Existing therapeutic vaccines targeting HPV oncoproteins E6 and E7 show limited immunogenicity and high production costs. Self-amplifying mRNA (saRNA) vaccines offer a promising alternative by enabling robust antigen expression at low doses. This study evaluated the immunogenicity and antitumor efficacy of a novel saRNA vaccine, JJ-saRNA-HPV01, targeting HPV16 E6/E7 in a preclinical mouse model.</p><p><strong>Methods: </strong>JJ-saRNA-HPV01, encoding an HPV16 E6-linker-E7 fusion protein, was encapsulated in lipid nanoparticles (LNP). Physicochemical properties (size, PDI, encapsulation efficiency, and zeta potential) were characterized, and in vitro expression was confirmed in 293 T cells by Western blot. Female C57BL/6 mice were immunized intramuscularly with single or double doses (0.1-5 μg). Immune responses were assessed by IFN-γ ELISpot, CD8⁺CD69⁺ T-cell activation, and tumor-infiltrating lymphocyte analysis. Antitumor efficacy was evaluated in TC-1 tumor-bearing mice, with prophylactic and long-term protection tested by tumor challenge and re-challenge. Statistical tests included one-way and two-way ANOVA with multiple comparisons and Kaplan-Meier survival analysis with Mantel-Cox test.</p><p><strong>Results: </strong>JJ-saRNA-HPV01 elicited potent, dose-dependent, E7-specific CD8⁺ T-cell responses in the mouse model. In therapeutic TC-1 models, both 0.1 and 1 µg doses markedly inhibited tumor growth (TGI = 93.0 and 95.7%) and improved survival (p < 0.001), with the 1 µg dose achieving complete regression and 91% survival. Prophylactic vaccination provided 100% protection and cured mice rejected tumor re-challenge, confirming durable E7-specific memory. Mechanistically, vaccination increased intratumoral CD8⁺ infiltration with limited CD4⁺ recruitment, elevated IFN-γ⁺ effector T-cell frequencies (p < 0.001), and reduced PD-1 expression on tumor-infiltrating lymphocytes by 33-55% (p < 0.05), indicating partial reversal of T-cell exhaustion and establishment of a more immunoactive tumor microenvironment.</p><p><strong>Conclusions: </strong>JJ-saRNA-HPV01 induces potent antitumor immunity at low doses (0.1-1 μg), by promoting T-cell infiltration, enhancing IFN-γ secretion, and downregulating PD-1 expression. Its dual prophylactic/therapeutic efficacy, dose-sparing advantage, and long-term protection support clinical translation in HPV-associated cancers, particularly in resource-limited settings. Future studies should focus on improving E6 immunogenicity and evaluation in combination with immune checkpoint inhibitors.</p>","PeriodicalId":520581,"journal":{"name":"Cancer immunology, immunotherapy : CII","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13612777/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148388467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Repurposing public sarcoma multi-omics for neoantigen discovery.","authors":"Panagiotis Mantas, Karen A Krogfelt","doi":"10.1007/s00262-026-04469-x","DOIUrl":"10.1007/s00262-026-04469-x","url":null,"abstract":"","PeriodicalId":520581,"journal":{"name":"Cancer immunology, immunotherapy : CII","volume":"75 7","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13332914/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148388523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The increased co-expression of SLC7A11 and PD-L1 was associated with poor prognosis in extranodal natural killer T-cell lymphoma patients.","authors":"Cuiying He, Yingzhen Yao, Xiaolin Wu, Meng Yue, Lingling Zhang, Xiaojie Fan, Yuan Li, Chen Zhao, Haisheng Liu","doi":"10.1007/s00262-026-04484-y","DOIUrl":"10.1007/s00262-026-04484-y","url":null,"abstract":"<p><p>Extranodal natural killer/T‑cell lymphoma (ENKTL) is a highly aggressive type of mature T and NK cell lymphoma that faces treatment challenges. Although immune checkpoint inhibitors (ICIs) have shown clinical activity in ENKTL, primary resistance and limited durable responses remain major obstacles. Our previous study demonstrated that the natural diterpenoid compound kayadiol exerted antitumor activity via p53/SLC7A11‑mediated ferroptosis in ENKTL cells. Cystine, through the solute carrier family 7 member 11 (SLC7A11)-a cystine/glutamate antiporter-serves as the primary regulator of cystine uptake for glutathione biosynthesis. To evaluate the expression patterns of SLC7A11 in ENKTL, we conducted immunohistochemistry (IHC) analyses on formalin‑fixed paraffin‑embedded (FFPE) specimens obtained from 42 newly diagnosed ENKTL patients. The results indicated that high expression of SLC7A11 was associated with decreased overall survival (OS) and progression‑free survival (PFS). Furthermore, the simultaneous detection of PD‑L1 expression revealed a correlation between the expressions of SLC7A11 and PD‑L1, with their mutual high expression also linked to an unfavorable prognosis. To further assess the co‑expression pattern of SLC7A11 and PD‑L1 in tumor cells, we performed fluorescent multiplex immunohistochemistry (mIHC). Notably, both SLC7A11 and PD‑L1 were confirmed to be predominantly localized to CD56⁺ neoplastic cells. The mIHC analysis further substantiated that elevated co‑expression of SLC7A11 and PD‑L1 was associated with a poor prognosis for ENKTL patients. These findings were externally validated in the GSE90597 cohort, where high SLC7A11 expression and high co‑expression were both associated with poorer OS, whereas PD‑L1 alone did not reach significance. Conversely, CD8⁺PD‑1⁺ tumor‑infiltrating T cells showed no statistically significant association with clinical outcomes. Our findings demonstrate that tumor cell‑specific co‑expression of SLC7A11/PD‑L1 is associated with a poor prognosis in ENKTL, suggesting that dual‑targeted therapy may enhance efficacy for these individuals.</p>","PeriodicalId":520581,"journal":{"name":"Cancer immunology, immunotherapy : CII","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13507008/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148388505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}